HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duhaylongsod, F. G. Articles by Wolfe, W. G. Search for Related Content PubMed PubMed Citation Articles by Duhaylongsod, F. G. Articles by Wolfe, W. G.

The Journal of Thoracic and Cardiovascular Surgery, Vol 102, 36-41, Copyright © 1991 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Barrett's esophagus and adenocarcinoma of the esophagus and gastroesophageal junction

FG Duhaylongsod and WG Wolfe
Department of General and Thoracic Surgery, Duke University, Durham, N.C.

Since 1985, 57 patients with adenocarcinoma of the esophagus and gastroesophageal (GE) junction have undergone surgical resection. In this group, 16 of the tumors arose in a Barrett's esophagus. There was a significant predilection toward white men above the age of 55 (15/16; 94%) in this subgroup. The mean proximal extent of abnormal columnar involvement was 5.4 cm above the gastroesophageal junction (range 2.5 to 11 cm). The mean location of the neoplasm centered in the distal esophagus 1.8 +/- 0.5 cm above the gastroesophageal junction. During the same time period, 30 patients with Barrett's esophagus were seen without associated adenocarcinoma. There were no statistical differences in the proximal extent of columnar involvement or the presence of reflux symptoms between the two groups. There were no significant differences in age, smoking history, and alcohol consumption between patients with benign or malignant Barrett's esophagus as compared to those with adenocarcinoma of the gastroesophageal junction not associated with Barrett's mucosa. The marked male predominance seen in the group with malignant Barrett's esophagus was in contrast to the benign cases (16/30; 53%) but was similar to the adenocarcinoma group, without recognized Barrett's esophagus (38/41; 93%). The mean location of the tumor in the latter was 0.9 +/- 1.2 cm above the gastroesophageal junction and was comparable to the location in the group with Barrett's adenocarcinoma. The 4-year survival rate of patients in the non-Barrett's adenocarcinoma group is approximately 30%. Of those with Barrett's adenocarcinoma, the present 4-year survival rate is 60%. The demographic and morphometric similarities between the Barrett's and non- Barrett's adenocarcinoma groups may be of primary importance in determining the true clinical prevalence of Barrett's adenocarcinoma. Our findings suggest that the sensitivity of endoscopic surveillance may be improved if biopsy specimens are concentrated within the distal 3 cm of the esophagus and the esophagogastric junction. Finally, the reason for the current difference in survival between the Barrett's and non-Barrett's adenocarcinoma groups is uncertain but may be related to endoscopic surveillance permitting earlier diagnosis and treatment.

This article has been cited by other articles:

				F. Yousef, C. Cardwell, M. M. Cantwell, K. Galway, B. T. Johnston, and L. Murray The Incidence of Esophageal Cancer and High-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis Am. J. Epidemiol., August 1, 2008; 168(3): 237 - 249. [Abstract] [Full Text] [PDF]

				L Murray, A Sedo, M Scott, D McManus, J M Sloan, L J Hardie, D Forman, and C P Wild TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort Gut, October 1, 2006; 55(10): 1390 - 1397. [Abstract] [Full Text] [PDF]

				S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF]

				G. Portale, J. H. Peters, J. A. Hagen, S. R. DeMeester, T. A. K. Gandamihardja, C. Tharavej, C.-C. Hsieh, and T. R. DeMeester Comparison of the Clinical and Histological Characteristics and Survival of Distal Esophageal-Gastroesophageal Junction Adenocarcinoma in Patients With and Without Barrett Mucosa Arch Surg, June 1, 2005; 140(6): 570 - 575. [Abstract] [Full Text] [PDF]

				M. S. Sabel, K. Pastore, H. Toon, and J. L. Smith Adenocarcinoma of the Esophagus With and Without Barrett Mucosa Arch Surg, July 1, 2000; 135(7): 831 - 836. [Abstract] [Full Text] [PDF]

				C. van de Ven, P. De Leyn, W. Coosemans, D. Van Raemdonck, and T. Lerut Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction Eur. J. Cardiothorac. Surg., June 1, 1999; 15(6): 769 - 773. [Abstract] [Full Text] [PDF]

				W. H. Steup, P. De Leyn, G. Deneffe, D. Van Raemdonck, W. Coosemans, and T. Lerut TUMORS OF THE ESOPHAGOGASTRIC JUNCTIONLong-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 85 - 95. [Abstract] [Full Text]